Last reviewed · How we verify
Oncovin
Oncovin is a Small molecule drug developed by University of Colorado, Denver. It is currently in Phase 2 development for Acute lymphoid leukemia, Burkitt's lymphoma, Diffuse non-Hodgkin's lymphoma, large cell. Also known as: Vincristine, Leurocristine, Vincristin.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 2 attrition
-2.0pp
Oncology drugs have higher Phase 2-to-Phase 3 attrition than average — many fail to show OS benefit in larger studies.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Oncovin |
|---|---|
| Also known as | Vincristine, Leurocristine, Vincristin |
| Sponsor | University of Colorado, Denver |
| Target | Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Approved indications
- Acute lymphoid leukemia
- Burkitt's lymphoma
- Diffuse non-Hodgkin's lymphoma, large cell
- Follicular non-Hodgkin's lymphoma
- Hodgkin's disease
- Nephroblastoma
- Neuroblastoma
- Non-Hodgkin's lymphoma
- Rhabdomyosarcoma
Common side effects
- Infections and infestations - Other, specify
- Neutrophil count decreased
- Alanine aminotransferase increased
- Febrile neutropenia
- Hyperglycemia
- Platelet count decreased
- Hypocalcemia
- White blood cell decreased
- Hyponatremia
- Peripheral sensory neuropathy
- Anemia
- Hypokalemia
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma (PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity (PHASE2)
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oncovin CI brief — competitive landscape report
- Oncovin updates RSS · CI watch RSS
- University of Colorado, Denver portfolio CI
Frequently asked questions about Oncovin
What is Oncovin?
What is Oncovin used for?
Who makes Oncovin?
Is Oncovin also known as anything else?
What development phase is Oncovin in?
What are the side effects of Oncovin?
What does Oncovin target?
Related
- Target: All drugs targeting Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1
- Manufacturer: University of Colorado, Denver — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Acute lymphoid leukemia
- Indication: Drugs for Burkitt's lymphoma
- Indication: Drugs for Diffuse non-Hodgkin's lymphoma, large cell
- Also known as: Vincristine, Leurocristine, Vincristin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing